Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells
- PMID: 14695199
Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells
Abstract
Migration-stimulating factor (MSF) is a 70-kDa motogenic protein previously reported to be expressed by fetal and cancer patient fibroblasts cultured in vitro and present in the serum of breast cancer patients. A 2.2-kb full-length MSF cDNA has been cloned and shown to be a truncated isoform of fibronectin generated from its primary gene transcript by a hitherto unrecognized intron read-through mechanism. MSF cDNA is identical to the 5' end of fibronectin cDNA, up to and including exon III-1a, and terminates in a novel 195-nucleotide 3' sequence. This MSF unique sequence is derived from the intron immediately downstream of exon III-1a in the fibronectin gene and is not found in any previously identified "full-length" fibronectin cDNA. MSF mRNA is 1000-fold less abundant than full-length fibronectin message in fetal fibroblasts and exhibits rapid biphasic decay kinetics previously associated with oncogenes and stress response molecules. MSF recombinant protein exhibits a potent and substratum-dependent motogenic activity, with half-maximal response manifest at 0.1-1.0 pg/ml. This activity is (a) mediated by the IGD amino acid motif; and (b) not expressed by (i.e., cryptic within) full-length fibronectin. In situ hybridization and immunohistochemistry confirm that MSF is expressed by tumor-associated fibroblasts and additionally indicate that it is also expressed by carcinoma cells and tumor-associated vascular endothelial cells. MSF, as a consequence of its potent bioactivities and expression by both stromal and carcinoma cell populations, is well placed to function as an epigenetic effector promoting cancer development.
Similar articles
-
The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3'-untranslated region-dependent nuclear sequestration of its precursor messenger RNA.Cancer Res. 2005 Dec 1;65(23):10742-9. doi: 10.1158/0008-5472.CAN-05-2038. Cancer Res. 2005. PMID: 16322219
-
Multi-factorial modulation of IGD motogenic potential in MSF (migration stimulating factor).Exp Cell Res. 2010 Sep 10;316(15):2465-76. doi: 10.1016/j.yexcr.2010.04.003. Epub 2010 Apr 18. Exp Cell Res. 2010. PMID: 20403349
-
Migration Stimulating Factor (MSF): Its Role in the Tumour Microenvironment.Adv Exp Med Biol. 2021;1329:351-397. doi: 10.1007/978-3-030-73119-9_18. Adv Exp Med Biol. 2021. PMID: 34664248
-
Migration stimulating factor (MSF): its structure, mode of action and possible function in health and disease.Symp Soc Exp Biol. 1993;47:235-51. Symp Soc Exp Biol. 1993. PMID: 8165568 Review.
-
Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention.Eye (Lond). 2010 Mar;24(3):450-8. doi: 10.1038/eye.2009.314. Epub 2009 Dec 18. Eye (Lond). 2010. PMID: 20019766 Review.
Cited by
-
Characterisation of Collagen Re-Modelling in Localised Prostate Cancer Using Second-Generation Harmonic Imaging and Transrectal Ultrasound Shear Wave Elastography.Cancers (Basel). 2021 Nov 5;13(21):5553. doi: 10.3390/cancers13215553. Cancers (Basel). 2021. PMID: 34771715 Free PMC article.
-
Anastellin, the angiostatic fibronectin peptide, is a selective inhibitor of lysophospholipid signaling.Mol Cancer Res. 2009 Feb;7(2):255-65. doi: 10.1158/1541-7786.MCR-08-0195. Epub 2009 Feb 10. Mol Cancer Res. 2009. PMID: 19208746 Free PMC article.
-
Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target.Mol Cell Proteomics. 2009 Apr;8(4):816-26. doi: 10.1074/mcp.M800331-MCP200. Epub 2008 Dec 23. Mol Cell Proteomics. 2009. PMID: 19117829 Free PMC article.
-
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.Clin Exp Immunol. 2012 Feb;167(2):195-205. doi: 10.1111/j.1365-2249.2011.04515.x. Clin Exp Immunol. 2012. PMID: 22235995 Free PMC article. Review.
-
Identification of a novel family of laminin N-terminal alternate splice isoforms: structural and functional characterization.J Biol Chem. 2009 Dec 18;284(51):35588-96. doi: 10.1074/jbc.M109.052811. J Biol Chem. 2009. PMID: 19773554 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Miscellaneous